CANCER IMMUNOLOGY AND IMMUNOTHERAPY CENTER

NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA.
J Immunol. 2011 Mar 15;186(6):3327-35.

Effects of Donor Age, Gender, and In Vitro Cellular Aging on the Phenotypic, Functional, and Molecular Characteristics of Mouse Bone Marrow-Derived Mesenchymal Stem Cells.
Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Loutradis D, Stefanidis K, Baxevanis CN, Papamichail M, Perez SA.
Stem Cells Dev. 2011 Feb 15. [Epub ahead of print]

Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
Tsavaris N, Voutsas IF, Kosmas C, Gritzapis AD, Baxevanis CN.
Invest New Drugs. 2010 Sep 7. [Epub ahead of print]

A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer.
Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA.
Cancer Immunol Immunother. 2010 Dec;59(12):1781-9.

HER-2/neu as a target for cancer vaccines.
Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M.
Immunotherapy. 2010 Mar;2(2):213-26. Review.

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN.
Clin Cancer Res. 2010 Jul 1;16(13):3495-506.

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD, Voutsas IF, Lekka E, Papamichail M, Baxevanis CN.
Cancer Res. 2010 Apr 1;70(7):2686-96.

A new era in anticancer peptide vaccines.
Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN.
Cancer. 2010 May 1;116(9):2071-80. Review.

Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E, Gritzapis AD, Perez SA, Tsavaris N, Missitzis I, Mamalaki A, Papamichail M, Baxevanis CN.
Cancer Immunol Immunother. 2010 May;59(5):715-27.

The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.
Dimitriadis A, Gontinou C, Baxevanis CN, Mamalaki A.
BMC Cancer. 2009 Oct 30;9:386.

HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor properties.
Gritzapis AD, Fridman A, Perez SA, La Monica N, Papamichail M, Aurisicchio L, Baxevanis CN.
Vaccine. 2009 Dec 10;28(1):162-70.

Cancer immunotherapy.
Baxevanis CN, Perez SA, Papamichail M.
Crit Rev Clin Lab Sci. 2009;46(4):167-89. Review.

Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin.
Vlahopoulos S, Gritzapis AD, Perez SA, Cacoullos N, Papamichail M, Baxevanis CN.
Vaccine. 2009 Jul 23;27(34):4704-8.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
Baxevanis CN, Perez SA, Papamichail M.
Cancer Immunol Immunother. 2009 Mar;58(3):317-24. Review.

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD, Voutsas IF, Lekka E, Tsavaris N, Missitzis I, Sotiropoulou P, Perez S, Papamichail M, Baxevanis CN.
J Immunol. 2008 Jul 1;181(1):146-54.

The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma).
Dimas K, Tsimplouli C, Anagnostopoulos AK, Mahaira L, Iliopoulou E, Perez S, Vougas K, Tsangaris GT.
Cancer Genomics Proteomics. 2008 May-Aug;5(3-4):175-237.

Translating immunity into cancer therapy: new findings from the first conference of the European Society for Cancer Immunology and Immunotherapy, an ESMO-EIS held in Athens, 15-17 November 2007.
Pawelec G, Perez S.
Cancer Immunol Immunother. 2008 Oct;57(10):1505-9.

Cancer immunotherapy: perspectives and prospects.
Perez SA, Papamichail M.
Adv Exp Med Biol. 2008;622:235-53. Review.

Clinical grade expansion of human bone marrow mesenchymal stem cells.
Sotiropoulou PA, Perez SA, Papamichail M.
Methods Mol Biol. 2007;407:245-63.

Immune properties of mesenchymal stem cells.
Sotiropoulou PA, Papamichail M.
Methods Mol Biol. 2007;407:225-43. Review.

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain.
Voutsas IF, Gritzapis AD, Mahaira LG, Salagianni M, von Hofe E, Kallinteris NL, Baxevanis CN.
Int J Cancer. 2007 Nov 1;121(9):2031-41.

A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GR.
Voutsas IF, Gritzapis AD, Alexis MN, Katsanou ES, Perez S, Baxevanis CN, Papamichail M.
J Immunol Methods. 2007 Jul 31;324(1-2):110-9.

Increased frequency of CD4+ cells expressing CD161 in cancer patients.
Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, Rigatos G, Papamichail M, Perez SA.
Clin Cancer Res. 2006 Dec 1;12(23):6901-9.

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN.
Cancer Immunol Immunother. 2007 May;56(5):601-13.

Characterization of a novel cell penetrating peptide derived from Bag-1 protein.
Niarchos DK, Perez SA, Papamichail M.
Peptides. 2006 Nov;27(11):2661-9.

Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN.
Cancer Res. 2006 May 15;66(10):5452-60.

Cell culture medium composition and translational adult bone marrow-derived stem cell research.
Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M.
Stem Cells. 2006 May;24(5):1409-10.

Fifth European progress in vaccination against cancer conference, PIVAC 5.
Cavallo F, Baxevanis CN.
Cancer Immunol Immunother. 2006 Jul;55(7):884-90.

Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.
Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A.
Cancer Immunol Immunother. 2006 Sep;55(9):1091-9.

Effect of IL-21 on NK cells derived from different umbilical cord blood populations.
Perez SA, Mahaira LG, Sotiropoulou PA, Gritzapis AD, Iliopoulou EG, Niarchos DK, Cacoullos NT, Kavalakis YG, Antsaklis AI, Sotiriadou NN, Baxevanis CN, Papamichail M.
Int Immunol. 2006 Jan;18(1):49-58.

Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells.
Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M.
Stem Cells. 2006 Feb;24(2):462-71.

Interactions between human mesenchymal stem cells and natural killer cells.
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M.
Stem Cells. 2006 Jan;24(1):74-85.

.